COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Expanded Access Use of Pemigatinib to Treat a Single Patient With Mixed Phenotype Acute Leukemia, B/Myeloid

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03906357
Expanded Access Status : No longer available
First Posted : April 8, 2019
Last Update Posted : April 9, 2019
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
Expanded access use of Pemigatinib to treat a single patient with mixed phenotype acute leukemia, B/myeloid.

Drug: Pemigatinib

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.

Intervention Details:
  • Drug: Pemigatinib
    Other Name: INCB054828

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult

Inclusion Criteria:


Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03906357

Sponsors and Collaborators
Incyte Corporation
Layout table for investigator information
Principal Investigator: Ellen Ritchie, MD Weill Cornell Medical College-New York Presbyterian Hospital
Layout table for additonal information
Responsible Party: Incyte Corporation Identifier: NCT03906357    
Other Study ID Numbers: I-54828-19-01
First Posted: April 8, 2019    Key Record Dates
Last Update Posted: April 9, 2019
Last Verified: April 2019